ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1923

Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Yoko Wada1, Takeshi Kuroda2, Masaaki Nakano3 and Ichiei Narita1, 1Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Health Administration Center, Niigata University, Niigata, Japan, 3Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ANCA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Vasculitis - Poster II: ANCA-Associated Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic vasculitides associated with ANCA specific for myeloperoxidase (MPO) or proteinase-3 (PR3), and includes microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). A high prevalence of venous thromboembolism has been reported in several cohort studies of patients with AAV, not only during active disease but also when patients are in remission. Recently, it has also been suggested that patients with AAV in the active stage are in a hypercoagulable state. However, the clinical significance of the increased incidence of venous thromboembolism among patients with AAV has not been fully recognized. Here we examined the relationship between markers for hypercoagulability and disease activity including inflammatory markers and kidney functions, and assessed the implication of abnormal coagulation status in patients with AAV.

Methods: Fifty-five patients who had been referred to Niigata University Hospital and diagnosed as having AAV (MPA (n=29), GPA (n=23), EGPA (n=3)) between 2009 and 2015 were recruited. Plasma fibrin degradation products (FDP), D-dimer, and activated thromboplastin time (APTT) were measured, and the APTT ratio was calculated and standardized using data from control plasma. Disease activity was assessed at the same time in accordance with the Birmingham Vasculitis Activity Score (BVAS). Other laboratory data including kidney function parameters and serum C-reactive protein (CRP) were also examined, and analyzed using Spearman’s rank correlation coefficient and stepwise multiple regression analysis to determine their relationship with coagulation parameters. A P value of <0.05 was taken to denote statistical significance.

Results: The mean value of FDP was elevated at 11.4 μg/ml (normal <9μg/ml), the mean D-dimer value was also elevated at 4.5 μg/ml (normal <1 μg/ml), and the mean APTT ratio was 1.15. In 44 patients, the APTT ratio was >1.01. Spearman’s rank correlation coefficient analysis showed that FDP and D-dimer were positively associated with CRP, daily urinary protein excretion, and BVAS, and negatively correlated with the estimated glomerular filtration rate (eGFR), whereas the APTT ratio was positively associated with BVAS. Although stepwise multiple regression analysis revealed no factor that significantly affected FDP or D-dimer, BVAS was selected as a positive independent variable affecting the APTT ratio (rho=0.3401, p=0.01186). In addition, the mean BVAS was significantly higher in patients with an APTT ratio of ≥1.01 (n=44), compared to patients with an APTT ratio of ≤1.0 (n=11) (16.1 ± 5.4 versus 11.2±5.9, p=0.0114).

Conclusion: Prolongation of APTT reflects AAV disease activity and is considered to be a possible biomarker in affected patients.


Disclosure: Y. Wada, None; T. Kuroda, None; M. Nakano, None; I. Narita, None.

To cite this abstract in AMA style:

Wada Y, Kuroda T, Nakano M, Narita I. Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/activated-partial-thromboplastin-time-reflects-disease-activity-in-patients-with-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activated-partial-thromboplastin-time-reflects-disease-activity-in-patients-with-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology